(2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;phosphoric acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;phosphoric acid
• 化学式: C12H21N6O8P
• 分子量: 408.3
• InChiKey: SKZXJJALGFIBLS-MDTVQASCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  262
• 氢给体数：
  9
• 氢受体数：
  12

文献信息

• LYOPHILIZED FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND
  申请人：Takeda GmbH

  公开号：EP2914289A1

  公开（公告）日：2015-09-09
• US9833410B2
  申请人：——

  公开号：US9833410B2

  公开（公告）日：2017-12-05
• [EN] LYOPHILIZED FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND<br/>[FR] FORMULATION LYOPHILISÉE COMPRENANT UN COMPOSÉ NEUTRALISANT GM-CSF
  申请人：TAKEDA GMBH

  公开号：WO2014068029A1

  公开（公告）日：2014-05-08

  The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM- CSF in view of lyophilisation, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction,is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.